Danièle Guyot-Caparros is graduated from the Ecole Supérieure de Commerce of Nancy in finance and accounting. Following international missions in audit, she joined Rhone Poulenc (now Sanofi) where she has held different positions with an increasing scope of responsibilities in finance on a European level and in business planning and performance monitoring on a worldwide level. Danièle Guyot-Caparros has been working as a consultant specialized in the life sciences and healthcare areas for 5 years.
Danièle Guyot-Caparros has been a director of Onxeo since 26 June 2013 and Chairperson of the Board of Directors since 22 May 2019. Her mandate will expire at the annual shareholders’ general meeting of 2022.
Danièle GUYOT-CAPARROS
CHAIRPERSON
JUDITH GRECIET
Doctor of Pharmacy with a master’s degree in management and pharmaceutical marketing, Judith Greciet spent some fifteen years working her way up through subsidiaries of international pharmaceutical companies. She has held major managerial positions with increasing operational and strategic responsibilities from leading sales teams, heading marketing and strategy departments (Pharmacia, Zeneca, LFB, Wyeth France (now Pfizer)) until she finally became President of the French subsidiary of the Japanese laboratory Eisai in June 2007. Throughout her career, Judith Greciet has cultivated a keen awareness of the marketing and business environment of drugs, in France in particular and more broadly in Europe, as well as confronting market access issues, particularly in the areas of oncology and immunology with innovative products such as Enbrel (rheumatology).
Appointed Chief Executive Officer of Onxeo in 2011, Judith Greciet pursued development of the company by remolding the strategy towards new growth-areas such as oncology.
Her mandate was renewed for 3 years at the annual shareholders’ general meeting of 2020.
JUDITH GRECIET
DIRECTRICE GÉNÉRALE
Thomas HOFSTAETTER
Thomas Hofstaetter holds a PhD in Molecular Biology.
He carried out his international career, especially in Germany, the United States and Japan, within international pharmaceutical groups (Wyeth, Aventis, etc.) on strategic positions at the highest level in external growth and business development. Over the past two years, until December 2011, he headed VaxInnate Corporation and is now Board Member of Bionor ASA.
Thomas Hofstaetter has been a director of Onxeo since 31 May 2012. His mandate will expire at the shareholders’ annual general meeting of 2021.
Thomas HOFSTAETTER
INDEPENDENT DIRECTOR
Nicolas TREBOUTA
Nicolas Trebouta is a Doctor of Medicine.
Co-founder of Chevrillon and Associates in 2000, Nicolas Trebouta has lead several buyouts within this structure including Picard frozen foods, CPI printing or Albingia insurance. Since 2004, he has been investing in biotechnology companies through his company Financière de la Montagne, either directly or through biotech funds. Nicolas Trebouta has been a shareholder of BioAlliance Pharma since 2008.
Financière de la Montagne has been a director since 29 June 2011. Their mandate will expire at the shareholders’ annual general meeting of 2023.
Nicolas TREBOUTA
DIRECTOR - REPRESENTING FINANCIÈRE DE LA MONTAGNE
Jean-Pierre BIZZARI
Jean-Pierre Bizzari, M.D., served as Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Mr. Bizzari is also an active board member in various biotech companies, such as Transgene in France, Halozyme Therapeutics and Celator Pharmaceuticals in the US. He has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses.
Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). He then joined Rhône-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997. From 2002 until 2008, Mr. Bizzari served as Vice President of Clinical Oncology Development at Sanofi-Aventis in Malvern, PA before joining Celgene.
Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada.
M. Jean-Pierre Bizzari has been appointed director on April 6, 2016. His mandate will expire at the shareholders’ annual general meeting of 2019.
Jean-Pierre BIZZARI
INDEPENDENT DIRECTOR
Christine GARNIER
Christine Garnier is co-founder of the firm AEC Partners and is Managing Partner since 1998. She graduated from ESCP Europe in 1984. Her consultant activity is specialized in corporate, international and operational strategies, evolutions in business models and organizations, and the optimization of performance across the life science industry. During the last twenty years, Christine Garnier has managed more than 200 assignments on primary and specialty care products, vaccine products, as well as medical device and OTC. She accompanies executive committees and operational and functional management in the development of vision, their strategies and the evolution of their organizations. The perimeters of her interventions concentrate on Europe and fast developing countries (South East Asia, Latin America…) as well as international and corporate headquarters. She provides her clients with a strong expertise in strategy and organization coupled by her skill to identify and initiate necessary transformations. Before joining AEC Partners, Christine Garnier previously worked for 12 years in the pharmaceutical industry holding marketing positions in Wyeth and international marketing and strategic planning at Rhone Poulenc Rorer.
Christine GARNIER
INDEPENDENT DIRECTOR
Julien Miara
Julien Miara is a Director at Invus. He joined in 2010 as an analyst in the Public Equity group, covering Biotechnology among other sectors.
In 2018, he was promoted to lead the team in Europe. Previously, he worked in investment banking at BNP Paribas in Paris and Société Générale in New-York, as well as in management consulting. Julien Miara received his Master of Management from EDHEC Business School in Lille (France) in 2009.
At its meeting on September 17, 2020, the Board of Directors of Onxeo co-opted Mr. Julien Miara, representing Invus Public Equities LP, as a director of the Company. This cooptation of Mr. Miara follows his appointment as observer to the Board of Directors on June 2, 2020 and will be submitted to the shareholders for approval at the Company’s next ordinary general meeting.
Julien Miara
DIRECTOR - REPRESENTING INVUS PUBLIC EQUITIES LP
Shefali Agarwal, MD
Dr. Shefali Agarwal is Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA(r) (niraparib) in ovarian cancer. Dr. Agarwal has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer. In addition to receiving her medical degree, Dr. Agarwal holds a master’s of public health and a master’s of science in business.
